

**IN THE CLAIMS:**

1. (Amended) A method of treating or preventing sexual dysfunction which comprises administering to a subject suffering or liable to suffer therefrom and in  
5 need of treatment or prevention an effective amount of a bombesin receptor antagonist.

Claims 2 -3 and 11-13: please delete.

- 10 14. (Amended) The method of claim [22] 1, wherein [the vasodilator is selected from] *the bombesin receptor antagonist is administered in combination with* alprostadil or phentolamine.

Claim 15: please delete.

- 15 16. (Amended) The method of claim [22] 1, wherein [the vasodilator is] *the bombesin receptor antagonist is administered in combination with* a compound that promotes production of NO.

- 20 21. (Amended) The method of claim [11] 1, wherein the bombesin receptor antagonist and ~~the~~ a vasodilator are simultaneously administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the vasodilator and a pharmaceutically acceptable carrier or diluent.

- 25 Please add the following new claims:

24. *The method of claim 5, wherein the sexual dysfunction is hypoactive sexual desire disorder.*
- 30 25. *The method of claim 5, wherein the sexual dysfunction is a sexual arousal disorder.*

26. *The method of claim 5, wherein the sexual dysfunction is an orgasmic disorder or anorgasmy.*

5 27. *The method of claim 5, wherein the sexual dysfunction is sexual pain disorder.*

28. *The method of claim 5, wherein the subject is receiving an antidepressant or antihypertensive.*

10

29. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the clitoris or vagina or on lubricant secretion.*

15 30. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.*

31. *The method of claim 30, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.*

20

32. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.*

25 33. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.*

34. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an oestrogen.*

30 35. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.*

36. *The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator.*

5 37. *The method of claim 6, wherein the sexual dysfunction is erectile dysfunction.*

38. *The method of claim 6, wherein the sexual dysfunction is psychogenic.*

39. *The method of claim 6, wherein the sexual dysfunction is drug-induced.*

10

40. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the penis.*

15 41. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.*

42. *The method of claim 6, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.*

20

43. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.*

25 44. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.*

45. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.*

30 46. *The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator.*